[Ip-health] U.S. Senate: Drug prices too high

Ruth Lopert ruth.lopert at gmail.com
Tue Dec 22 08:22:17 PST 2015


Completely agree

On Tue, Dec 22, 2015 at 11:20 AM, Ellen Shaffer <ershaffer at cpath.org> wrote:

> Suits me. Of course, U.S. negotiators have indeed walked away from a given
> drug, price, or company, in the context of Medicaid and the VA, which is
> why the industry blocked Medicare from exercising this power.
>
> In any case, it will be useful to shift focus away from quibbling with
> drug co.s about whether they deserve just a few more years of monopoly
> protection to recoup the costs of biologics (or any new drugs), after which
> the miracle of pure competition will kick in; and focus on comprehensive
> solutions that will lower prices.  - Ellen
>
> On Tue, Dec 22, 2015 at 7:17 AM, Ruth Lopert <ruth.lopert at gmail.com>
> wrote:
>
>> The US needs to regulate prices - either directly or indirectly. I can't
>> see how 'negotiating' alone will make much difference unless there is
>> leverage, and willingness to walk away from the negotiation.
>>
>> On Sun, Dec 20, 2015 at 2:08 PM, Ellen Shaffer <ershaffer at cpath.org>
>> wrote:
>>
>>> The hearing by the Senate Committee on Aging
>>> <
>>> http://www.aging.senate.gov/press-releases/senate-aging-committee-holds-1st-hearing-on-off-patent-rx-drug-price-spikes-
>>> >,
>>> led by Sens. Collins and McCaskill, presents impressive documentation
>>> that
>>> drug prices are exorbitant, and that stimulating competition is an
>>> inadequate solution, including from generics.  Generics are not available
>>> for many medicines, including those off-patent; quality varies; and even
>>> generic prices may be high. Debates on patent term lengths are important
>>> but skirt the central problem. Voluntary "discount" programs by drug cos.
>>> are window dressing. The U.S. government must have the authority to
>>> negotiate prices, if not to outright set prices, as do other countries
>>> with
>>> equal or better results for innovation.
>>>
>>>
>>> http://www.aging.senate.gov/press-releases/senate-aging-committee-holds-1st-hearing-on-off-patent-rx-drug-price-spikes-
>>>
>>> Senate Aging Committee Holds 1st Hearing on Off-Patent Rx Drug Price
>>> Spikes
>>> COMMITTEE EXAMINES CAUSES, IMPACTS, AND POTENTIAL SOLUTIONS TO DRAMATIC
>>> PRICE INCREASES OF OFF-PATENT DRUGSWednesday, December 9, 2015
>>>
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfI3BeGKPHjCJrbpRs9oIhxph5nadeEDp7k439SzbaoItM-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejpAfJ5ctkeEia3S00W8pQpjT3ebv0MsnFC86F6DZFm68lOtOljpuSzEguw-2BSauNmLk5l0PHUo-2Bmk9kc0N0i25I0pEpUaiGFTYTD8NO-2B02lTh5gYzWtzv45cjs1OjJrVe3-2BR2t0c6Wp-2BOfRir77fqMCQ-3D
>>> >
>>> for
>>> a copy of Senator Collins’ opening statement
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfI-2BEcppiBNcWTiDcHA-2FsONr600O8NIXlPt7G9KqGKuO9k-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejmNuL9wbF7DklKhgGgyooeHJ7uJtlOvVHxXbJC6WsbpSOtD4pSCUoo8SnMvkh8UB6M7LkYAXQiVtrp4tOcyAFj9nBg3dPxhD98FpaD-2BpHmDFfdFIVxqn9G0oWmBkOOyyy3nWJxXv4L5XjGUqL0lToGM-3D
>>> >
>>> for
>>> a copy of Senator McCaskill’ s opening statement
>>>
>>> Washington, D.C.—The Senate Special Committee on Aging, led by Chairman
>>> Susan Collins and Ranking Member Claire McCaskill, held the first in a
>>> series of hearings the Committee will conduct to investigate recent
>>> instances of abrupt and dramatic price increases in prescription drugs
>>> that
>>> are no longer protected by patents. The hearing, titled *Sudden Price
>>> Spikes in Off-Patent Drugs: Perspectives from the Front Lines*, began the
>>> Committee’s bipartisan examination of this issue.
>>>
>>>      “Prescription drugs are vital to the health and well-being of all
>>> Americans, especially our nation’s seniors, 90 percent of whom take at
>>> least one prescription drug in any given month,” said Senator Collins.
>>> “For
>>> many decades, federal policy has sought to strike the right balance
>>> between
>>> maintaining the incentives needed to promote innovation and the
>>> development
>>> of new drugs and keeping medicines affordable.  That balance we have
>>> struck
>>> never anticipated companies acquiring off-patent drugs and then jacking
>>> up
>>> their prices to enormous heights, and doing so, as one executive
>>> essentially put it, ‘because I can.’  In some instances, these price
>>> increases have negatively affected patients’ and doctors’ access to
>>> off-patent drugs.  One goal of our bipartisan investigation is to
>>> understand why such companies can impose egregious price increases on
>>> off-patent drugs they have acquired and what policies we should consider
>>> to
>>> counter this disturbing practice.”
>>>
>>>       “There’s a line at which huge price increases on prescription drugs
>>> go from rewarding innovation to price gouging,” said Senator McCaskill.
>>> “In
>>> particular, when these price hikes occur without any therapeutic changes
>>> or
>>> improvements to the drug, it raises troubling questions about whether
>>> companies are taking advantage of the patients who depend on their
>>> products
>>> for survival.”
>>>
>>>       This year alone, Americans are expected to spend more than $328
>>> billion on prescription drugs.  Of this amount, individuals will pay
>>> about
>>> $50 billion out-of-pocket.  The federal government will pick up another
>>> $110 billion in payments through Medicare, Medicaid, Veterans Affairs,
>>> and
>>> other programs.
>>>
>>>       Witnesses for the hearing included: Dr. Erin Fox, Director, Drug
>>> Information Service, University of Utah Health Care and Adjunct Associate
>>> Professor, University of Utah College of Pharmacy, Dept. of
>>> Pharmacotherapy;  Dr. David Kimberlin, Professor and Vice Chair for
>>> Clinical and Translational Research and Co-Director, Division of
>>> Pediatric
>>> Infectious Diseases, Department of Pediatrics, University of Alabama at
>>> Birmingham;Dr. Gerard Anderson, Professor, Health Policy and Management,
>>> Medicine, and International Health, Johns Hopkins University; and Mr.
>>> Mark
>>> Merritt, President & Chief Executive Officer, Pharmaceutical Care
>>> Management Association.
>>>
>>>
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfI0lld1likDe1GpQRZgA-2BxD8P6CvM-2F-2BtI0nZ0RIXndc0w-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejuK4f4BuTtMHYticAVduEVVMC8GhHmnuUr3OBeD9Nb298BPvql42y1x3eTf2AgF0JNaS2VfRWOQbW5e-2BKK7K4E-2F-2FKkuu5n3LCR62Bg0RsM-2BP4fpyzK0t4TDkNp37QjQrobMIZz-2FjVoKaUnWAZIicUgE-3D
>>> >
>>> for
>>> a copy Dr. Erin Fox’s testimony
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfIa-2BLEvK5sjQcFnwQBbbYv2L7fJzpSyiZkIsAWjEpRYs0-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejtW6lYQMZMBp0R7FpKXUA4YSNpZLUdQlTFQ2wLgFTBCdDRyGtcDaxrXv2aAyYN0l1fHJPerfdp0wF-2FEz4JWF8MSWF6swrdnS8xx-2FEx1u8JxyEQYE2n3y3yV6g-2BqQcCjyM6B9n4wfFIRT24bphlN-2BuWI-3D
>>> >
>>> for
>>> a copy of Dr. David Kimberlin’s testimony
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfIhyneEhjFW1vN-2F2fQCYPfMB-2FwHJVCFmrGHfIs7YF7bLc-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejgb-2FIrB7AnFJxTpW3228m0-2BOxfuEWzIZ4mdmsPrEvUat-2F0T1bZrOhm2H3B8DHGqsCl4v9qltGx4Ir2bbj2eYxc5aKBasDXEZUMyvMw56gAMyXmlGfQo0Eo02mHwgucZsSYv4IQTjn0waWjqX6994HRc-3D
>>> >
>>> for
>>> a copy of Dr. Gerard Anderson’s testimony
>>> Click HERE
>>> <
>>> http://email.prnewswire.com/wf/click?upn=J6qBPRVgziwoCR2OIJDNfVqt7DYgFcv5-2FETn5EzMeD6vQ1EMdqpZ-2BiVG15BGbxfIAKpWrnlxcUmCRqyx-2BJ0T4i-2F5CA4VgKwBN6IOyAZGMGM-3D_3JD5Sj2EQq2uoUbP9uH12ECLf3oNLZBMKHlw6TtF0qUBQN5Df27XMbgQuqOYqLz3bjaVDWePZdMXksFTmqWDqCeYhKhRsA58FdbyJ0UzFAMNvkNYgV-2BeXaXTrn2wJ5q9RWIrMHu2-2BeTmHQuGCCrFwydCurYlzaSOrGYHB8WDTG8sLcn-2BIcLYgTgyOtulTWMbKwKFoEF659m-2BhoTf6rOejsqJ0tOjHJXKbaLqXupJfHFcefZtwH4iNtnXodEHDTzDpqPEz4PXqeJ4-2FSky25ax7BioIvHuxyTLTtgl3umAZ1OSeDBMSPuQNfBhzjoVxEWIXjrLtP7ykM3sEdR5pOC6byUUJ09GZDb-2FoKj99qxAPi8-3D
>>> >
>>> for
>>> a copy of Mr. Mark Merritt’s testimony
>>> - Ellen Shaffer
>>>
>>>
>>> --
>>> Dr. Ellen R. Shaffer, PhD MPH
>>> Asst. Clinical Professor, UCSF
>>> Co-Director, Center for Policy Analysis on Trade and Health/CPATH
>>> P.O. Box 29586
>>> San Francisco, CA 94129-0586
>>> Phone 415-922-6204
>>> www.cpath.org
>>> _______________________________________________
>>> Ip-health mailing list
>>> Ip-health at lists.keionline.org
>>> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org
>>>
>>
>>
>
>
> --
> Dr. Ellen R. Shaffer, PhD MPH
> Asst. Clinical Professor, UCSF
> Co-Director, Center for Policy Analysis on Trade and Health/CPATH
> P.O. Box 29586
> San Francisco, CA 94129-0586
> Phone 415-922-6204
> www.cpath.org
>
>



More information about the Ip-health mailing list